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Novel thiophene derivatives with sulfonamide, isoxazole, 
benzothiazole, quinoline and anthracene moieties as potential 
anticancer agents
A novel series of thiophenes having biologically active sul-
fonamide 2–11, 3-methylisoxazole 12, 4-methoxybenzo[d]
thiazole 13, quinoline 14, 15, benzoylphenylamino 16, and 
anthracene-9,10-dione 17 moieties were prepared. Struc-
tures of the newly synthesized compounds were estab-
lished by elemental analysis and spectral data. All newly 
synthesized compounds were evaluated for their in vitro 
anticancer activity against human breast cancer cell line 
(MCF7). Most of the screened compounds showed cyto-
toxic activities compared to doxorubicin as a positive con-
trol. Compounds 6, 7, 9 and 13 (IC50 values 10.25, 9.70, 9.55 
and 9.39 µmol L–1) revealed higher cytotoxic activities than 
that of doxorubicin (IC50 = 32.00 µmol L–1). Also, compounds 
5, 8 and 10 were found nearly as active as doxorubicin 
(IC50 28.85, 23.48 and 27.51 µmol L–1).
Keywords: thiophenes, sulfonamides, isoxazole, benzothia-
zole, quinoline, anthracene, anticancer activity
 
Thiophenes have been reported to possess interesting biological and pharmacological 
activities where several derivatives are used as antibacterial (1–3), anti-inflammatory (4), 
anticancer (5, 6), and antiviral agents (7). Also, sulfonamides constitute an important class 
of drugs, with several types of pharmacological agents possessing anticancer activity (8–
12), among others. A large number of structurally novel sulfonamides have ultimately 
been reported to show substantial anticancer activity in vitro and in vivo (13). Several mech-
anisms have been reported for anticancer activity of sulfonamide compounds and the 
most prominent of these mechanisms was thought to be the inhibition of carbonic anhy-
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inhibitor was suggested by Chegwidden and Spencer (17). These compounds may reduce 
the provision of bicarbonate for the synthesis of nucleotides and other cell components 
such as membrane lipids. Also, isoxazole, benzothiazole, quinoline and anthracene de-
rivatives posseses a wide range of biological activities, including anti-inflammatory (18), 
antibacterial (19) and anticancer activity (20–22). In addition, several novel quinoline de-
rivatives have been reported to show substantial anticancer activities (23–26). Also, a host 
of structurally novel sulfonamides have recently been reported to show substantial anti-
cancer activity in vitro and/or in vivo. Since the discovery of E-7010 (I , 27), sulfonamides 
have emerged as an important class of anticancer agents, which interact with a wide range 
of different cellular targets such as disruption of microtubules assembly and carbonic 
anhydrase inhibition (17). Some of these compounds having the NH of the sulfonamide 
group substituted by an aryl group showed potent anticancer activity such as KD5170 (II) 
and PXD101 (III) (28). In continuation of our work (29–33), it seemed of interest to design 
and synthesize a novel series of thiophenes bearing biologically active sulfonamide, isox-
azole, benzoxazole, quinoline and anthracene moieties and to evaluate their anticancer 
activity.
EXPERIMENTAL
Melting points (uncorrected) were determined in open capillaries on a Gallenkemp 
melting point apparatus (Sanyo Gallenkemp, UK). Pre-coated silica gel plates (silica gel 
0.25 mm, 60 G F 254, Merck, Germany) were used for thin layer chromatography. Dichlo-
romethane/methanol (9.5:0.5, V/V) mixture was used as a developing solvent system. IR 










































Fig. 1. Biologically active compounds I–III and structures of target compounds 2–17.
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Japan). NMR spectra in DMSO-d6 were recorded on Bruker Ac-500 ultra shield NMR spec-
trometer (d in ppm, Bruker, Switzerland) at 500 MHz, using TMS as an internal standard. 
Elemental analyses were performed on a Carlo Erba 1108 Elemental Analyzer (Heraeus, 
Germany). Elemental analyses of all compounds were within ± 0.4 % of the theoretical 
values. Starting compound, 1-(thiophen-2-yl)ethanone was purchased from Sigma (USA). 
Syntheses
3-(Dimethylamino)-1-(thiophen-2-yl)prop-2-en-1-one (1) was prepared according to 









methylpyrimidin-2-yl)-4-(3-oxo-3-(thiophen-2-yl)prop-1-enylamino)benzenesulfonamide (10) and 
(Z)-N-(4,6-dimethylpyrimidin-2-yl)-4-(3-oxo-3-(thiophen-2-yl)prop-1-enylamino)benzenesulfon-
amide (11). General procedure. – A mixture of (1) (1.81 g, 0.01 mol) and sulfonamide deriva-
tives (0.01 mol) in ethanol (20 mL) containing acetic acid (10 mL) was refluxed for 6 h. The 
obtained solid was recrystallized from dioxane while hot to give 2–11.
(Z)-3-(3-Methylisoxazol-5-ylamino)-1-(thiophen-2-yl)prop-2-en-1-one (12). – A mixture of 
1 (1.81 g, 0.01 mol) and 3-methyl-5-aminoisoxazole (0.98 g, 0.01 mol) in ethanol (20 mL), 
containing acetic acid (10 mL) was refluxed for 6 h. The obtained solid was recrystallized 
from dioxane to give 12.
(Z)-3-(4-Methoxybenzo[d]thiazol-2-ylamino)-1-(thiophen-2-yl)prop-2-en-1-one (13). – A mix-
ture of (1) (1.81 g; 0.01 mol) and 2-amino-4-methoxybenzothiazole (1.80 g, 0.01 mol) in 
ethanol (20 mL) containing (10 mL) acetic acid was refluxed for 8 h. The obtained solid was 
recrystallized from ethanol to give 13.
(Z)-3-(Quinolin-3-ylamino)-1-(thiophen-2-yl)prop-2-en-1-one (14) and (Z)-3-(2-methyl qui-
nolin-4-ylamino)-1-(thiophen-2-yl)prop-2-en-1-one (15). – A mixture of 1 (1.81 g, 0.01 mol) and 
3-aminoquinoline or 4-amino-2-methylquinoline (0.01 mol) in absolute ethanol (20 mL)
glacial acetic acid (10 mL) was refluxed for 18 h. The obtained solid while hot was recrystal-
lized from dioxane to give 14 and 15, respectively.
(Z)-3-(4-Benzoylphenylamino)-1-(thiophen-2-yl)prop-2-en-1-one (16) and (Z)-2-(3-oxo-3-
(thiophen-2-yl)prop-1-enylamino)anthracene-9,10-dione (17). – A mixture of 1 (1.81 g, 0.01 
mol) and 4-aminophenyl-phenyl-methanone or 2-aminoanthracene-9,10-dione (0.01 mol) 
in ethanol (20 mL), containing acetic acid (10 mL) was refluxed for 8 h. The solid ob-
tained, while hot, was recrystallized from dioxane to give (16) and (17), respectively. 
Physical, chemical and spectral data of newly synthesized compounds are given in Ta-
bles I and II.
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Table I. Physical and analytical data of the newly synthesized compounds
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Table II. Spectral data of the newly synthesized compounds






3340, 3248, 3190 (NH, NH2), 
3101 (CH arom.), 1628 
(C=O), 1360, 1157 (SO2)
6.1, 7.1 (2d, 2H, CH=CH, J = 7.1, 
7.6 Hz), 7.2-8.0 (m, 9H, Ar-H + 
SO2NH2), 10.4 (s, 1H, NH, D2O 
exchangeable)
94.8, 115.8 (2), 128.5 (2), 
128.6, 130.4, 138.0, 142.5, 
144.2, 145.7, 146.4, 180.3
3
3425, 3320, 3185 (NH, NH2), 
3100 (CH arom.), 2970, 2897 
(CH aliph.), 1646 (C=O), 
1380, 1130 (SO2)
6.4, 7.4 (2d, 2H, CH=CH, J = 7.7, 
7.8 Hz), 6.7 (s, 2H, NH2, D2O- ex-
changeable), 7.5-7.9 (m, 7H, 
Ar-H), 8.1 (s, 1H, NH imino; 
D2O- exchangeable), 10.3 (s, 1H, 
NH aniline; D2O-exchangeable), 
11.7 (s, 1H, SO2NH, D2O- ex-
changeable )
94.6, 115.6 (2), 128.4 (2), 
128.6, 129.8, 137.7, 138.6, 
144.4, 145.7, 146.5, 158.0, 
180.2
4
3464, 3370 (2NH), 3066  
(CH arom.), 2966, 2860  
(CH aliph.), 1632 (C=O), 
1589 (C=N), 1334, 1161 (SO2)
2.3 (s, 3H, CH3), 6.1 (d, 1H, 
CHCO; J = 7.2 Hz), 6.4 (s, 1H, CH 
oxazole), 7.2 (d, 1H, CH-NH; J = 
7.5 Hz), 7.3-7.9 (m, 7H, Ar-H), 
10.4 (d, 1H, NH; J = 7.4 Hz), 11.2 
(s, 1H, SO2NH, D2O-exchange-
able)
12.0, 95.3, 95.5, 116.0 (2), 
128.6 (2), 128.8, 130.6, 
132.7, 133.5, 144.2, 145.1, 
146.3, 153.2, 169.8, 180.3
5
3317, 3209 (2NH), 2924, 2860 
(CH aliph.), 1685 (C=O), 
1635 (C=N), 1340, 1192 (SO2)
2.1 (s, 6H, 2CH3), 6.1 (d, 1H, 
CHCO; J = 7.2 Hz), 7.2 (d, 1H, 
CH-NH; J = 7.4 Hz), 7.3-7.9 (m, 
7H, Ar-H), 10.5 (d, 1H, NH; J = 
7.8 Hz), 11.7 (s, 1H, SO2NH, 
D2O-exchangeable)
5.8, 10.3, 95.5, 100.0, 116.0 
(2), 128.7 (2), 130.1, 130.6, 
133.5, 142.1, 145.1, 145.6, 
146.2, 155.5, 161.4, 183.4
6
3390, 3290 (2NH), 3090  
(CH arom.), 2940, 2860  
(CH aliph.), 1635 (C=O), 
1593 (C=N), 1373, 1138 (SO2)
6.1, 7.2 (2d, 2H, CH=CH; J = 7.2, 
7.3 Hz), 6.4, 7.3 (2d, 2H, CH=CH 
thiazole; J = 7.7 Hz), 7.4-8.0 (m, 
7H, Ar-H), 10.4 (d, 1H, NH; J = 
7.0 Hz), 11.7 (s, 1H, SO2NH, 
D2O-exchangeable)
94.9, 108.1, 115.8 (2), 128.6 
(2), 129.9, 130.4, 132.6, 
133.3, 135.1, 142.4, 144.1, 
146.4, 170.0, 180.3
7
3340, 3290 (2NH), 3065  
(CH arom.), 2970, 2836  
(CH aliph.), 1646 (C=O), 
1610 (C=N), 1370, 1183 (SO2)
6.1, 7.2 (2d, 2H, CH=CH, J = 7.6, 
7.7 Hz), 6.4, 7.8 (2d, 2H, CH-CH 
pyrazole, J = 7.1, 7.3 Hz), 7.3-8.0 
(m, 12H, Ar-H), 10.4 (d, 1H, NH, 
J = 7.6 Hz), 11.7 (s, 1H, SO2NH, 
D2O-exchangeable)
95.4, 99.9, 116.0 (2), 124.2 
(2), 127.4, 128.6 (2), 128.7, 
130.6 (2), 131.8, 138.2, 
139.5, 142.2, 143.9, 144.0, 
144.9, 145.6, 146.3, 180.4
8
3310, 3280 (2NH), 3055  
(CH arom.), 2940, 2860  
(CH aliph.), 1636 (C=O), 
1597 (C=N), 1396, 1176 (SO2)
6.4, 7.2 (2d, 2H, CH=CH, J = 7.1, 
7.3 Hz), 7.3-8.1 (m, 11H, Ar-H), 
10.4 (d, 1H, NH, J = 7.8 Hz), 11.7 
(s, 1H, SO2NH, D2O-exchange-
able)
95.0, 112.0, 113.2, 115.8 (2), 
128.6 (2), 128.8, 129.9, 
135.3, 139.9, 140.1, 143.2, 
144.2, 145.7, 146.3, 152.8, 
180.4
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9
3464,3267 (2NH), 3035  
(CH arom.), 2939, 2870  
(CH aliph.), 1655 (C=O), 
1582 (C=N), 1338, 1195 (SO2)
6.4, 7.3 (2d, 2H, CH=CH, J = 7.0, 
7.2 Hz), 7.4-8.5 (m, 10H, Ar-H), 
10.4 (d, 1H, NH, J = 7.6 Hz), 11.7 
(s, 1H, SO2NH, D2O-exchange-
able)
95.3, 112.1, 115.6 (2), 128.6 
(2), 130.0, 132.5, 133.7, 
143.8, 144.8, 145.6, 146.3, 
158.3 (2), 180.3, 183.3
10
3433, 3370 (2NH), 3060  
(CH arom.), 2947, 2862  
(CH aliph.), 1632 (C=O), 
1593 (C=N), 1363, 1153 (SO2)
2.3 (s, 3H, CH3), 6.4, 7.3 (2d, 2H, 
CH=CH, J = 7.1, 7.4 Hz), 7.4-8.3 
(m, 9H, Ar-H), 10.4 (d, 1H, NH,  
J = 8.1 Hz), 11.7 (s, 1H, SO2NH, 
D2O-exchangeable)
23.2, 95.2, 114.6, 115.4 (2), 
128.6 (2), 129.7, 129.9, 133.4, 
142.2, 144.7, 145.6, 146.3, 
156.5, 168.7, 180.3, 183.6
11
3210 (2NH), 3066 (CH 
arom.), 2993, 2816 (CH 
aliph.), 1697 (C=O), 1635, 
1593 (2C=N), 1373, 1157 
(SO2)
2.2 (s, 6H, 2CH3), 6.4, 7.2 (2d, 2H, 
CH=CH, J = 7.3, 7.5 Hz), 6.7-7.9 
(m, 8H, Ar-H), 10.4 (d, 1H, NH,  
J = 8.0 Hz), 11.7 (s, 1H, SO2NH, 
D2O-exchangeable)
23.0 (2), 95.1, 99.6, 115.2 (2), 
128.4 (2), 128.6, 129.9, 133.3, 
134.3, 144.5, 145.6, 146.3, 
167.3, 172.0, 180.3, 183.0
12
3132 (NH), 3082 (CH arom.), 
2940, 2836 (CH aliph.), 1642 
(C=O), 1635 (C=N)
2.3 (s, 3H, CH3), 6.4 (s, 1H, CH 
isoxazole), 6.2, 7.3 (2d, 2H, 
CH=CH; J = 6.9 Hz), 7.5-7.9 
(m, 3H, Ar-H), 10.3 (d, 1H, NH,  
J = 7.5 Hz)
12.1, 95.8, 100.6, 128.4, 
133.7, 142.3, 145.4, 146.0, 
160.3, 169.9, 180.4
13
3421 (NH), 3093 (CH 
arom.), 2930, 2860 (CH 
aliph.), 1645 (C=O),  
1635 (C=N)
3.9 (s, 3H, OCH3), 6.6, 7.2 (2d, 2H, 
CH=CH; J = 8.1, 8.3 Hz), 7.3-7.5 
(m, 6H, Ar-H), 8.5 (d, 1H, NH;  
J = 6.8 Hz)
55.7, 108.1, 113.2, 113.6, 
121.4, 128.8, 129.0, 136.5, 
136.9, 138.1, 140.2, 142.0, 
149.8, 165.1, 185.8
14
3209 (NH), 3047 (CH arom.), 
2920, 2836 (CH aliph.), 1651 
(C=O), 1612 (C=N)
6.2, 6.5 (2d, 2H, CH=CH; J = 7.2, 
7.3 Hz), 7.4-8.0 (m, 8H, Ar-H),  
8.9 (s, 1H, N=CH, quinoline), 
11.8 (d,1H,NH, J = 7.5 Hz)
94.9, 127.0, 127.1, 127.2, 
127.3, 128.6, 129.8, 130.2, 
133.1, 134.9, 143.0, 143.1, 
144.8, 145.8, 146.5, 180.2
15
3340 (NH), 3078 (CH 
arom.), 2970, 2830 (CH 
aliph.), 1643 (C=O),  
1620 (C=N)
2.4 (s, 3H, CH3), 5.9, 7.1 (2d, 2H, 
CH=CH; J = 7.0, 7.2 Hz), 6.4 
(s, 1H, CH quinoline), 7.2-8.1  
(m, 7H, Ar-H), 8.4 (d, 1H, NH;  
J = 7.8 Hz)
23.9, 92.3, 101.9, 122.2, 
123.1, 128.2, 128.9, 129.0, 
129.5, 136.9, 138.1, 140.2, 
142.0, 142.6, 153.6, 160.2, 
185.8
16
3433 (NH), 3046 (CH 
arom.), 2930, 2840 (CH 
aliph.), 1640 (2C=O)
6.2, 7.3 (2d, 2H, CH=CH, J = 7.4, 
7.5 Hz), 7.2-8.0 (m, 12H, Ar-H), 
10.5 (d, 1H, NH; J = 7.1 Hz)
113.2, 115.6 (2), 128.6 (4), 
130.1 (4), 131.0, 133.8, 134.7, 
148.8, 151.3, 152.8, 153.9, 
163.4, 190.2
17
3444 (NH), 3070 (CH 
arom.), 2960, 2840 (CH 
aliph.), 1670, 1650 (3C=O)
6.5, 6.9 (2d, 2H, CH=CH; J = 7.0, 
7.2 Hz), 6.9-8.2 (m, 10H, Ar-H), 
10.7 (d, 1H, NH; J = 7.3 Hz)
100.9, 112.0, 119.6, 121.0, 
126.3, 128.5 (2), 129.5, 132.9 
(2), 133.3 (2), 133.6, 134.3, 
134.5, 134.8, 141.4, 145.7, 
180.0, 183.3 (2)
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In vitro anticancer activity
Cytotoxic activity was measured in vitro for the newly synthesized compounds using 
the SulfoRhodamine-B stain (SRB) assay (35). Cells were plated in 96-multiwell microtiter 
plates (104 cells per well) for 24 h before treatment with the compound, to allow attachment 
of cells to the plate wall. Test compounds were dissolved in DMSO and diluted with saline 
to the appropriate concentration. Different concentrations of the compounds under test (10, 
25, 50 and 100 µmol L–1) were added to the cell monolayer. Triplicate wells were prepared for 
each individual dose. Monolayer cells were incubated with the compound(s) for 48 h at 37 °C 
and in an atmosphere of 5 % CO2. After 48 h, the cells were fixed, washed, and stain ed for 30 
min with 0.4 % (m/V) SRB in 1 % acetic acid. Excess unbound dye was removed by four 
washes with 1 % acetic acid and attached stain was recovered with Tris-EDTA buffer. Color 
intensity was measured in an enzyme-linked immunosorbent assay ELISA reader. The rela-
tion between the surviving fraction and drug concentration was plotted to get the survival 
curve for the breast tumor cell line after the specified time. The molar concentration required 
for 50 % inhibition of cell viability (IC50) was calculated and the results are given in Table III.
Table III. In vitro anticancer screening of the newly synthesized compounds against 
the human breast cancer cell line MCF7
Compound
Compound concentration (µmol L–1)
IC50








































































































aMean ± S.E, n = 3.
426
M. M. Ghorab et al.: Novel thiophene derivatives with sulfonamide, isoxazole, benzothiazole, quinoline and anthracene moieties as 




The current research deals with the synthesis of a new series of thiophene derivatives 
with sulfonamide, isoxazole, benzothiazole, quinoline and anthracene moieties through 
reaction of 2-acetyl thiophene with sulfa-drugs, aromatic amines and heterocyclic aro-
matic amines, and evaluation of their anticancer activity.
Schemes 1 and 2 display the synthesis of thiophenes having the biologically active 
sulfonamide 2–11, 3-methylisoxazole 12, 4-methoxybenzo[d]thiazole 13, quinoline 14, 15, 
benzoylphenylamino 16, and anthracene-9,10-dione 17 moieties.
Enaminone derivatives are highly reactive intermediates extensively used for the syn-
thesis of heterocyclic compounds. Thus, treatment of 3-(dimethylamino)-1-(thiophen-2-yl)
prop-2-en-1-one (1) with sulfonamide derivatives in refluxing ethanol/acetic acid mixture 
afforded the corresponding sulfonamide derivatives 2–11. Structures of the latter products 
were assigned on the basis of their analytical and spectral data. 1H NMR spectra of com-
pounds 2–11 support the assumption that these structures were in Z-form and not in E-
form, while the coupling constant of doublet signals for olefinic protons was equal to 7.0–
7.8 Hz. Z-form was stabilized by intramolecular hydrogen bonding.
The IR spectra of the reaction products showed in each case three absorption bands 
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absorption band in the 1697–1628 cm–1 region and absorption bands due to SO2 functions 
in the 1396–1130 cm–1 region. 1H NMR spectra of compounds 2–11 revealed a doublet in 
the 6.1–7.4 ppm region corresponding to the CH=CH group.
Also, interaction of compound 1 with 3-methyl-5-aminoisoxazole furnished the cor-
responding 3-methylisoxazole derivative 12. (Z)-3-(3-Methylisoxazol-5-ylamino)-1-(thio-
phen-2-yl)prop-2-en-1-one (12) was proven on the basis of elemental analysis and spectral 
data. Its IR spectrum showed bands at 3132 (NH) and 1642 cm–1 (C=O). The 1H NMR spec-
trum in DMSO-d6 revealed signals at 2.3 ppm due to the CH3 group and at 6.4 ppm cor-
responding to CH isoxazole. In addition, the corresponding benzothiazole derivative 13 
was obtained in good yield via reaction of 1 with 4-methoxybenzo[d]thiazol-2-amine. The 
IR spectrum of 13 exhibited bands at 3421 (NH) and 1645 cm–1 (C=O). The 1H NMR spec-
trum of compound 13 revealed signals at 3.9 ppm attributed to the OCH3 group and at 8.5 
ppm due to the NH group. Quinoline derivatives (14 and 15) were obtained via reaction of 
1 with quinolin-3-amine or 2-methylquinolin-4-amine, respectively, in a refluxing ethanol/
acetic acid mixture. Structures of compounds 14 and 15 were established on the basis of 
elemental analysis and spectral data. The IR spectrum of 14 showed bands at 3209 cm–1 
(NH), 1651 cm–1 (C=O), and 1612 cm–1 (C=N). The 1H NMR spectrum of 14 revealed signals 
at 8.9 ppm due to N=CH of quinoline and 11.8 ppm corresponding to the NH group. The 
IR spectrum of 15 exhibited bands at 3340 cm–1 (NH), 1643 cm–1 (C=O) and 1620 cm–1 (C=N). 
1H NMR spectrum of 15 revealed signals at 2.4 ppm attributed to the CH3 group and at 8.4 
ppm corresponding to the NH group. Interaction of 1 with 4-aminophenyl-phenyl-metha-
none gave the corresponding benzoylphenylamino derivative 16. Its IR spectrum showed 
bands at 3433 (NH), and 1640 cm–1 (2C=O). The 1H NMR spectrum of 16 showed a multiplet 
for aromatic protons. Finally, interaction of 1 with 2-aminoanthracene-9,10-dione yielded 
the corresponding anthracene-9,10-dione derivative 17. Compound 17 was proven on the 
basis of elemental analysis and spectral data. Thus, its IR spectrum showed bands at 3444 
cm–1 (NH) and 1670, 1650 cm–1 (3C=O). The 1H NMR spectrum of 17 revealed the presence 
of a doublet at 6.5 and 6.9 ppm due to CH=CH groups, a multiplet at 6.9–8.2 ppm attribu ted 
to aromatic protons, and a signal at 10.7 ppm due to the NH group (Scheme 2).
In vitro anticancer activity
The newly synthesized compounds were evaluated for their in vitro anticancer activ-
ity against the human breast cancer cell line MCF7. Doxorubicin was used as the reference 
drug. Table III shows the in vitro cytotoxic activity of the newly synthesized compounds. 
Most of the tested compounds exhibited significant activity compared to doxorubicin. It 
was found that thiophenes containing biologically active sulfathiazole 6, sulfaphenazole 
7, sulfadiazine 9, or benzothiazole 13 moieties with respective IC50 values of 10.25, 9.70, 9.55, 
and 9.39 µmol L–1 exhibited 3.1- to 3.4-fold higher anticancer activity than the reference 
drug with the IC50 value of 32.00 µmol L–1. Further, thiophenes bearing the biologically 
active sulfamethoxazole 5, sulfapyridine 8 and sulfamethazine 10 with respective IC50 
values of 28.85, 23.48, and 27.51 µmol L–1 were nearly as active as doxorubicin. On the 
other hand, compounds 2, 3, 11, 12, 14 and 15 revealed slightly lower activity than that of 
doxorubicin. Thiophene derivatives showed that the cell killing potency against the breast 
cancer cell line as follows: 13 > 9 > 7 > 6 > 8 > 10 > 5 doxorubicin.
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CONCLUSIONS
The objective of the present study was to synthesize and investigate the anticancer 
activity of some novel thiophene derivatives carrying the biologically active sulfonamide, 




(9) and (Z)-3-(4-methoxybenzo[d]thiazol-2-ylamino)-1-(thiophen-2-yl)prop-2-en-1-one (13) 
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enylamino)benzene-sulfonamide (5), (Z)-4-(3-oxo-3-(thiophen-2-yl)prop-1-enylamino)-N-
(pyridin-2-yl)benzenesulfonamide (8) and (Z)-N-(4-methylpyrimidin-2-yl)-4-(3-oxo-3-
(thiophen-2-yl)prop-1-enylamino)benzenesulfonamide (10) were nearly as active as 
doxorubicin.
Biological screening of the test compounds could offer an encouraging framework in 
this field, which may lead to the discovery of even more potent anticancer agents.
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